#### ORIGINAL RESEARCH

# RETRACTED ARTICLE: Preparation of novel pirfenidone microspheres for lung-targeted delivery: in vitro and in vivo study

# Dianbo Li Liping Gong

Department of Thoracic Surgery, Linyi Tumor Hospital, Linyi, Shandong, People's Republic of China



Correspondence: Liping Gong Department of Thoracic Surgery, Linyi Tumor Hospital, 6 Cemetery Street, Lanshan District, Linyi, Shandong, 276001, People's Republic of China Email opktec@163.com



Abstract: The aim of this study was to develop and charterize pirfenio ne (PF)-loaded chitosan microspheres for lung targeting. The microspheres were epared us g the emulsionsolvent evaporation method and characterized by as ssing morphol p Acle size, and zeta smooth and integrated surfaces. potential. The microspheres had a spherical nature with high the zeta *r* cential was 20.3±1.4 mV. The particle size of microspheres was  $4.6\pm$ μm, nulat n of PF could reach the state The in vitro release results indicated that e obtained h of sustained release with a biphasic lug n ase pattern. was observed that there was no rapment efficiency and that of drug release significant difference in both the percentage of before and after the stability rady. In vivo, the coulated relative bioavailability indicated of PF when it was encapsulated in microspheres. According to greater pulmonary absorpti histopathological studies, no istological ch ge occurred to the rat lung after the administration of PF-loaded chitosan micros res.

Keywords: pirfe to chitosan, ....ospheres, in vitro release

#### Introductio

PF) is orally effective, pyridine, synthetic compound that has been nidone 1 for nt of idiopathic pulmonary fibrosis (IPF) in many countries the world.<sup>1</sup> Although the mechanism of action of PF is not very clear, the arou vitro data and animal models of pulmonary fibrosis show that PF has existing ntifibrotic, anti-inflammatory, and antioxidant properties and it is classified as an unosuppressant.<sup>2-8</sup> The antioxidant properties of PF may contribute to its antiinflammatory effects, and these, in turn, may account for some of PF's antifibrotic effects.9,10 To date, several PF clinical studies have been conducted in patients with IPF. Its evaluation in Phase II and Phase III clinical trials led to the approval of PF for the treatment of IPF in Japan in 2008 and in Europe in 2011,<sup>11,12</sup> and PF is now indicated for the treatment of patients with IPF (when forced vital capacity is  $\geq$  50% of predicted value, carbon monoxide diffusing capacity is  $\geq$ 35% of predicted value and a 6-minute walk test distance is  $\geq 150$  m).<sup>13</sup>

In vivo, administration of PF in fed and fasted states reduces overall exposure, maximal plasma concentration ( $C_{\rm max}$ ) values (reduced by 50% when administered with food), and the rate of absorption.<sup>14–16</sup> In clinical studies, PF binds mainly to plasma albumin in the human body with a mean binding rate of 50%–58%, but it was not widely distributed in other tissues. The results of a population pharmacokinetic study showed that the apparent oral steady state volume of distribution of PF was about 70 L.<sup>14–16</sup>

Because of the above pharmacokinetic properties and its narrow therapeutic index, the use of oral PF is very difficult in a clinical management setting and requires

Drug Design, Development and Therapy 2016:10 2815-2821

2815

© 2016 Li and Gong. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraph 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php). frequent serum concentration monitoring. The developed PF intravenous dosage that comes from the laboratory may contain a solubilizing agent, which has been reported to be a potentially toxic agent, and so we limited the use of this formulation. To overcome these limitations of PF, local immunosuppression by the inhaled route of administration is a potential approach to directly target the smaller airways, with improved bioavailability for the lung tissue, minimal or even zero systemic side effects, and improved pulmonary function.<sup>17</sup>

Chitosan (CS) is a polysaccharide polymer, similar in structure to cellulose. CS has been proven to be a useful and effective carrier for microspheres drug delivery through the inhalation route due to its low toxicity, biocompatibility, biodegradability, and mucoadhesive properties as well as macromolecule permeation enhancement.<sup>18,19</sup> It has been confirmed that spray-dried CS microspheres have a low toxicity in cell lines of human origin from airway and alveolar regions of the pulmonary tract; this is an encouraging index for the safe use of the dry powder inhalation.<sup>20</sup>

The main objective of this study was to develop and characterize PF-loaded CS microspheres (PFCSMs) for lung targeting. The developed formulations were characterized by assessing morphology, particle size, and zeta potential.

# Materials and methods Materials

PF (≥95%) was purchased from BeierKa Propharm Co., Ltd. (Wuhan, People's Republic of China). Sow-molecular weight CS of 75%–85% deacetylation was purchased from Hengshuo Pharma Co., Ltd. (Wuhan People's Republic of China). High-performance liquit chrom tography (Hr LC)grade acetonitrile and method were obtained from Sigma (Sigma-Aldrich, Shangha, People's Republic of China). All other reagents and solverts were at least of analytical grade. Distilled water was used in a the examinents.

# Preparation of *CE*-loaded CS microsphere

An emulsion-solvert evaporation method described previously in the literature was used to prepare the PFCSMs.<sup>21</sup> Briefly, 100 mg of PF was dissolved in 5 mL of methylene chloride, and 300 mg CS was dissolved in a surfactant solution (10 mL of 2.5% w/v aqueous solution of polyvinyl alcohol). Afterward, the PF solution was added dropwise into a 10 mL CS solution in a 100 mL flask with stirring at 400 rpm. This was followed by homogenization for 1 minute (220 W, 2 s/cycle). First, oil in water crude emulsion was obtained using a probe sonicator. The sonication step was repeated twice until the desired size was obtained. After sonication, the produced PF-loaded CS emulsion was then stirred overnight in a fume hood in an uncovered beaker to allow for the evaporation of methylene chloride. The solid microspheres were collected after storage under vacuum for 48 hours at room temperature.

# Morphology

The external morphology of microspheres was observed with field-emission scanning electron microscopy (SEM). Lyophilized microspheres were morphed onto stubs using double-sided adhesive tape with conclusive effect and analyzed using SEM. In Sulf study, electrons are transmitted from specimer surface. The putture was taken under inert condition with an electron microscope (magnification ×200).

#### Characteric tion

To determine the Preportent, microspheres were dissolved in acet is and restracted followed by HPLC sis. Briefly, 20 mg of PFCSMs was dissolved in anal 10 L acetonitri This suspension was vigorously mixed exing to get a clear solution and then separated and by v filtered . a 0.45 mm filter to remove the polymeric The clear solution was analyzed for PF content using de e HPLC method. The percentages of drug loading (DL) and entrapment efficiency (EE) of the microspheres were lculated using the following formula:

 $\%DL = \frac{\text{Weight of drug in microspheres}}{\text{Weight of microspheres}} \times 100$  $\%EE = \frac{\%DL}{\%\text{Theoretical loading}} \times 100$ 

# Particle size

A nanoparticle size analyzer (Mastersizer 3000; Malvern Instruments, Malvern, UK) was used to determine the particle size of microspheres. To calculate volume mean diameter, PFCSMs suspended in ethanol and sonicated for 2 minutes were used as the sample. No dissolution or agglomeration of the sample was obtained from the measurements, and each sample was determined in triplicate.

#### In vitro release

The release of PF was evaluated by incubating the PF suspensions or PFCSMs (20 mg) in 50 mL of phosphate buffer solution (pH 7.4 at  $37^{\circ}C\pm0.5^{\circ}C$ ) via the dialysis bag method.<sup>21</sup>

Characterization of PFCSMs for lung targeting

At time intervals of 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours, the collected supernatants (500  $\mu$ L) were passed through a 0.22  $\mu$ m filter membrane and analyzed for PF content using reverse-phase HPLC. The chromatographic conditions refer to the method reported previously by Meng and Xu.<sup>22</sup>

## Stability studies

According to the International Council on Harmonization guidelines, an accelerated stability study has to be carried out on the pharmaceutical dosage form at  $40^{\circ}C\pm 2^{\circ}C/75\%\pm 5\%$  relative humidity (RH). For the present study, developed formulations were subjected to accelerated stability study. The formulations were placed in a stability chamber at  $40^{\circ}C/75\%$  RH for a period of 30 days and then removed. After that, the %EE was determined and in vitro release studies carried out. The %EE and dissolution profiles were compared with the %EE and drug release profile of the same formulation before the stability studies.

#### In vivo studies

All animal study protocols were approved by the Institutional Animal Care and Use Committee at the Linyi Tumor Hospital and adhered to the guidelines of the Institutional Animal Care and Use Committee. Twelve Sprague Dawley rats we 200–250 g (approximately 7 weeks old) were purch sed from the animal center. Animals were housed microis tor cages under positive-pressure ventila Jn mai ained closed-shelf and laminar-flow racks to yoid with pathogens, odors, or noises. The ar mals w noused under terilized for standard laboratory condition and water were available ad libitum. sofore experiment, the rats were kept in a state of fing for 8 how Twelve Sprague domly elected and divided into two Dawley rats were r groups (six in each, oup) ne rats were anesthetized using urethane, which was all inistered arough an intraperitoneal upine position. According to injection the the ts lying a previously public that method, the trachea was exposed, and E-240 polyethylene tubing was inserted into one section the tracheal in a jon.<sup>23</sup> The sample was administered into the rat lung using a dy-powder inhaler. The powder administration was made by insufflation of 3 mL of air contained in a syringe. The insufflator was weighed before and after powder filling as well as after administration to determine the actual amount of sample released and aerosolized into the lung. The blood sample was collected from the PE-10 polyethylene tubing embedded into the caudal vein of the rats.

Group 1 rats were administered a single intratracheal dose of native PF (10 mg/kg); Group 2 rats were administered

a single intratracheal dose of PFCSMs (10 mg/kg). Blood samples (0.5 mL) were collected into heparinized tubes from the caudal vein at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration. Plasma samples were immediately centrifuged at  $4,000 \times g$  for 10 minutes and frozen at  $-70^{\circ}$ C until analysis. At the end of pharmacokinetic studies, samples of lung, liver, and kidney were collected from the sacrificed animals of both groups. Tissue samples were washed in ice-cold saline, blotted with a paper towel to remove excess fluid, and stored at  $-20^{\circ}$ C until analysis.

At the end of in vivo studies, secoles (lung, liver, and kidney) for histological analysis were preserved by immersion in 4% phosphate-buffer is paraformatichyde before washing overnight in running wear, dehy ating through alcohol and clearing in xylene, an other embedding in paraffin wax. The second (5 µm in thickness) were stained with bunatoxyle and eosie and observed using SEM (magnificate ×500). Sale was used as the control.

#### Statistical analysis

the obtained data was analyzed using the GraphPad Prism offware (GraphPad Software, Inc., San Diego, CA, USA) and expressed as mean  $\pm$  standard deviation. Comparisons betwee the wo sets of data were made using Student's *t*-test chaired data. When multiple comparisons against a single control were made, one-way analysis of variance was used, followed by the Tukey–Kramer multiple comparisons test. Differences were considered significant when P < 0.05.

# **Results and discussion** Physicochemical characterization

The PFCSMs were prepared successfully. The SEM revealed that the microspheres were homogeneous in size and had spherical shape with smooth and integrated surfaces (Figure 1). In addition, the microspheres showed relatively porous surfaces, which was due to the rapid evaporation of residual solvents such as methylene chloride during the




Figure I Scanning electron microscopy images of PF-loaded CS microspheres. Notes: (A) Magnification ×5,000; (B) magnification ×500. Abbreviations: PF, pirfenidone; CS, chitosan.

drying process. Currently, pulmonary delivery of PF is mainly via the dry-powder inhaler. The preparation of PF differs quite significantly in terms of the techniques and pharmacokinetic properties. The present study adopted the oil-in-water method to prepare the PF microspheres because the drug-saturated water solution used as the aqueous phase can effectively prevent the drug in the organic phase from diffusing out to the aqueous phase, thus greatly increasing the drug-loading capacity and encapsulation efficiency of the microspheres.

The volume mean diameter values of the prepared PFCSMs fall in the range of 4.31 to 4.78  $\mu$ m. The mean particle size of microspheres was 4.6±0.3  $\mu$ m, and the zeta potential was 20.3±1.4 mV, which indicated that there was a large number of positive charges on the surface of microspheres. Previous literature has reported that the higher the absolute value of the zeta potential (more than 15 mV) is, the stronger the electrostatic repulsion between particles will be, which makes the dispersal system more stable without aggregation and sedimentation.<sup>24</sup> The %EEs and %DL of PF in the prepared formulations were determined using HPLC. The data reveal that the %EEs values of the loaded PF fall in the range of 78.4% to 86.2% and the %DL, 5.4% to 6.7%.

#### In vitro release

The release profiles of PF from suspensions and PFoSMs are illustrated in Figure 2. As can be seen from the form, the microspheres showed a fast initial please of a f (about 25%) within the first 2 hours and are hed a plate within 4 hours, which was followed by a relaxely slow release.

At the end of the experiment, over 61% of PF was completely released. At the early stage, a burst release phenomenon was observed because the drug molecules were encapsulated on the surface of microspheres, which may easily diffuse out initially. The in vitro release profile of microspheres was best explained using the Korsmeyer–Peppas model with highest  $r^2$ =0.9853. The values for zero-order, first-order, Higuchi, and Weibull model were found to be 0.8214, 0.8419, 0.8928, and 0.9128, respectively.

# Stability studies

According to the International Co cil on h nonization guidelines, an accelerated stabil study was nducted. After being stored at 40°C a . 75% i develo ed formulations appeared to be st he as the dried a1 s showed no collapse or contraction. was oserved that there was no significant difference in both e %EE / a that of drug release before and after stability su n addition, particle size and zeta potential me urements showed no change in stability during the storage pl edure. Hence, both formulations found to be stable. wer

## In v o studi s

PFCSMs contratracheally administered in rats to evaluate the cohsorption. The plasma concentration-time profiles of PF after intratracheal administration of the PFCSMs and native PF in rats are shown in Figure 3. Pharmacokinetic arameters (Table 1), such as  $C_{\max}$ , the time of maximum concentration ( $T_{\max}$ ), and the area under the curve (AUC<sub>0-t</sub>), were used to assess potential differences in the pulmonary absorption. After administration, the plasma concentration of




Figure 2 In vitro drug release profiles of PF-loaded CS microspheres and free PF (n=6). Abbreviations: PF, pirfenidone; CS, chitosan.




Figure 3 Plasma concentration-time profiles of PF after a single intratracheal administration of native drug and ministration (n=6) Abbreviations: PF, pirfenidone; CS, chitosan.

native PF increased rapidly and reached a  $C_{\text{max}}$  of 562 ng/mL in 60 minutes  $(T_{max})$ . PFCSMs spray-dried powders gave a  $C_{\rm max}$  of 1,154 ng/mL in 60 minutes, which was significantly different from that of the native PF (P < 0.05). For PFCSMs, the AUC<sub>0-7</sub> was 2,899.8±259.6 ng·h/mL, which was higher than that of native PF. The major obstacle against the opment of sustained pulmonary drug delivery formul ions is that the most appropriate aerodynamic size for part. les to be respirable  $(0.5-5 \,\mu\text{m})$  is also the optimal. te for t rapid uptake by the macrophages in e alveo r region Therefore, in this study, the partic siz as suitable for pulmonary drug deligry and consignificantly PF. As we as know, CS improve the AUC related to **div** has been reported to be ble to impl the absorption of

Table I Pharmaco	etic a	irameters	of PF	after a	single
intratracheal administra	of	nativ dr	ug and m	nicrosphe	res to
rats (n=6)					

Parame rs	Intratracheal			
	Native drug	Microspheres		
T <sub>max</sub> (h)	1.3±0.4	2.1±1.1		
$t_{1/2}$ (h)	2.1±0.8	7.8±1.4*		
C <sub>max</sub> (ng/mL)	956.5±125.7	1,568.7±172.7*		
AUC <sub>0-t</sub> (ng·h/mL)	1,581.4±165.3	2,899.8±259.6*		
AUC <sub>0-∞</sub> (ng·h/mL)	1,985.1±171.4	3,362.5±315.5*		
MRT (h)	5.3±1.7	9.5±1.4		
CL (L/h)	11.2±2.4	2.9±0.6*		

**Notes:** Native drug and microspheres; \**P*<0.05. Data presented as mean ± SD. **Abbreviations:** PF, pirfenidone;  $t_{1/2}$ , half-life time;  $C_{max}$ , maximal plasma concentration; AUC, area under the curve; MRT, mean residence time; CL, clearance;  $T_{max}$ , the time of maximum concentration. macrone recule by opening the tight junctions of epithelial cells. In addition, CS nanoparticles have been used to increase the uptake of active molecules across mucosal urfaces.<sup>25,26</sup>

In some orgeted formulations such as microspheres, more fibridrugs and excipients would be accumulated in necific tissues (lung), and therefore, it was necessary to verify the biocompatibility and safety of these tissues and the microspheres formulation. Compared to the placebo group, the microsphere formulations did not show any degenerative changes in the cytoarchitecture of the tissue (lung), as shown in Figure 4. Throughout the experiment, the rats that were given PFCSMs did not develop any histological changes in the tissue of lung.

#### Conclusion

In this study, PFCSMs were prepared using the emulsionsolvent evaporation method and characterized by assessing morphology, particle size, and zeta potential. The microspheres had a spherical nature with highly smooth and integrated surfaces. The particle size of microspheres was  $4.6\pm1.7 \mu m$ , and the zeta potential was  $20.3\pm1.4 mV$ . The in vitro release results indicated that the obtained formulation of PF could reach a state of sustained release with a biphasic drug release pattern. It was observed that there was no significant difference in both the %EE and that of drug release before and after the stability study. In vivo, the calculated relative bioavailability indicated greater pulmonary absorption of PF when it was encapsulated in microspheres. According




Figure 4 Histopathological studies of lung (A), liver (B), and kidney (C) in (a) control group; for native PF; (c) PF-loaded CS microspheres. Magnification ×500. Abbreviations: PF, pirfenidone; CS, chitosan.

to histopathological studies, no histological change occurr to the rat lung after the administration of PFCSMs.

# Disclosure

The authors report no conflicts of interest in his wor

# References

- 1. Puglisi S, Torrisi SE, Vindigni V, et al prespectives ananagement of idiopathic pulmonary fibrosis *et er A*, *Chronic Dis.* 2, 5;7(2): 108–120.
- 2. Mediavilla-Varela M, Boateng L, Noyes D, Antonia C. The anti-fibrotic agent pirfenidone synergized with cisplatin in killing dumor cells and cancer-associated fibroble S. *BMC L acer.* 2016;16(1):176.
- Zanotti S, Bragato C, Zucca ba thet al. Anti-forotic effect of pirfenidone in muscle derived bibrobant from Drugenne muscular dystrophy patients. *Life S* 2016, p5:127–2
- Jin SF, Ma Lu, Liu ZL, and ST, Zhang, AP, He Y. XL413, a cell division cycle 7 kina, inhibite the anti-fibrotic effect of pirfenidone on TGF-β1-stimu. 23H10T1/2 cells via Smad2/4. *Exp Cell Res.* 2015; 339(2):289–299.
- 5. Bayhan Z, Zeren S, K FE, et al. Antiadhesive and anti-inflammatory effects of pirfenidone in postoperative intra-abdominal adhesion in an experimental rat model. *J Surg Res.* 2016;201(2):348–355.
- Aravena C, Labarca G, Venegas C, Arenas A, Rada G. Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. *PLoS One.* 2015;10(8):e0136160.
- Chen JF, Liu H, Ni HF, et al. Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats. *PLoS One*. 2013;8(12):e83593.
- Poletti V, Ravaglia C, Tomassetti S. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. *Expert Rev Respir Med.* 2014;8(5): 539–545.

9. Oku Shipite T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and factors in bleomycin-induced murine pulmonary fibrosis. *Eur J Pharmacol.* 2008;590(1–3):400–408.

- Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. *J Pharmacol Exp Ther*. 1999;289(1):211–218.
  Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2005;171(9):1040–1047.
- Taniguchi H, Ebina M, Kondoh Y, et al; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. *Eur Respir J.* 2010; 35(4):821–829.
- Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet*. 2011;377(9779):1760–1769.
- European Medicines Agency. Esbriet (Pirfenidone) Hard Capsules: EU Summary of Product Characteristics, 2014. Available at http://www. ema.europa.eu. Accessed January 5, 2015.
- US FDA. Esbriet (Pirfenidone) Capsules: US Prescribing Information, 2014. Available at http://www.accessdata.fda.gov. Accessed January 5, 2015.
- European Medicines Agency. Esbriet (Pirfenidone): CHMP Assessment Report, 2011. Available at http://www.ema.europa.eu. Accessed October 21, 2014.
- E-Sherbiny IM, E-Baz NM, Yacoub MH. Inhaled nano- and microparticles for drug delivery. *Glob Cardiol Sci Pract*. 2015;2015:2.
- Suarato G, Li W, Meng Y. Role of pH-responsiveness in the design of chitosan-based cancer nanotherapeutics: a review. *Biointerphases*. 2016;11(4):04B201.
- Dünnhaupt S, Barthelmes J, Rahmat D, et al. S-protected thiolated chitosan for oral delivery of hydrophilic macromolecules: evaluation of permeation enhancing and efflux pump inhibitory properties. *Mol Pharm.* 2012;9(5):1331–1341.

- Grenha A, Grainger CI, Dailey LA, et al. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. *Eur J Pharm Sci.* 2007; 31(2):73–84.
- Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman M. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. *Mol Pharm.* 2010;7(1):86–93.
- Meng H, Xu Y. Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation. *Drug Des Devel Ther*. 2015;9: 3369–3376.
- Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. *Pharm Res.* 1996;13(1):80–83.
- Dong Y, Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. *Biomaterials*. 2004;25(14):2843–2849.
- Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. *Eur J Pharm Sci.* 2005;25(4–5): 427–437.
- Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. *Pharm Res.* 1999;16(10):1576–1581.

#### Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal

**Dove**press